When Dr. Maria Koufaki and her team at the University of Manchester peered into tumors under their microscopes, they found something unexpected: tiny immune cells that act like quarterbacks calling the plays for cancer destruction. Their discovery, published in the journal Immunity, reveals that rare activated dendritic cells are the essential coaches that help other immune cells win the fight against tumors.
Scientists have known that dendritic cells exist for years, but nobody fully understood their exact role in fighting cancer. The problem was that researchers lacked good tools to study these cells in action. "Modern immunotherapies rely on strong and coordinated immune responses, yet many people still do not benefit from these treatments," said Dr. Koufaki, the study's first author.
To solve this puzzle, the Manchester team created the first mouse models ever designed to specifically label or remove activated dendritic cells. These special mouse models let the scientists see exactly what happens when these cells are present versus absent. What they discovered changed everything: without activated dendritic cells, the cancer-killing T cells could neither wake up properly nor keep fighting once inside tumors.
"Activated dendritic cells do not just launch the antitumor immune responses, they are also essential for sustaining them within the tumor itself," said senior author Santiago Zelenay. This means these cells are not just starting the immune system's attack against cancer — they are keeping it going.
The findings matter because immunotherapy, a treatment that helps the body's own immune system fight cancer, does not work for everyone. Some tumors resist treatment entirely, while others stop responding over time. Dr. Koufaki believes that learning to boost activated dendritic cells could help more patients benefit from immunotherapy. "If we can find ways to boost activated dendritic cells, we may be able to strengthen the immune system's response to cancer and help more patients benefit from immunotherapy, including some whose cancers currently resist treatment."
Dr. Marianne Baker, a research manager at Cancer Research UK who was not involved in the study, called the new mouse models a valuable tool. "The models developed as part of this study could help scientists unlock ways to boost these revolutionary treatments," she said. Immunotherapies already save lives, she noted, but understanding why they work for some people and not others remains a major goal.
The research is still early, and scientists need to do more work before these findings lead to new treatments for patients. But the discovery offers a promising new avenue: instead of only focusing on T cells — the soldiers of the immune system — researchers may now be able to strengthen the quarterbacks that organize them. That shift in thinking could eventually help immunotherapy reach more people.